Welcome to the e-CCO Library!

DOP059: New human gut xenograft mouse model for intestinal fistulas
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bruckner R.S.*1,2, Marsiano N.3, Nissim-Eliraz E.3, Nir E.3, Lang S.1,2, Spalinger M.1,2, Rogler G.1,4, Yagel S.5, Scharl M.1,4, Shpigel N.Y.3 SysmedIBD EU Research Consortium

Created: Wednesday, 20 February 2019, 10:36 AM
DOP059: New human gut xenograft mouse model for intestinal fistulas
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bruckner R.
Perianal fistulae, Enteroenteric fistula, Immunology, Mouse Model
Files: 1
DOP05: Adipose-derived stem cells from Crohn’s disease patients show antigen presenting cell-like properties
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Serena*1, M. Terrón-Puig1, M. Ejarque1, F. Algaba-Chueca1, E. Maymó-Masip1, M. Millan2, M. Menacho3, E. Espin4, M. Martí4, S. Fernández-Veledo1, J. Vendrell1

Created: Friday, 22 February 2019, 9:41 AM
DOP05: Adipose-derived stem cells from Crohn’s disease patients show antigen presenting cell-like properties
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Carolina Serena
Created: Tuesday, 28 May 2019, 3:32 PM
Microbiota, Crohn’s disease, Cell-based therapies, Immunology, Mesenchymal cell, Inflammosomes
Files: 1
DOP05: Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Revés, Joana
Created: Tuesday, 30 April 2024, 5:03 PM
DOP05: Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based study
Year: 2022
Source: ECCO'22
Authors: Canete Pizarro, F.C.(1);Vela, E.(2);Calafat, M.(1);Clèries, M.(2);Mañosa, M.(1);Domènech, E.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP05: Perioperative Dietary Therapy in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Michel Adamina
Created: Tuesday, 23 June 2020, 5:40 PM
DOP05: Perioperative Dietary Therapy in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Michel Adamina
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP05: Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Melon, E.(1)*;Veny, M.(1);Corraliza, A.M.(1);Garrido-Trigo, A.(1);Esteller, M.(1);Rodrigo, M.(2);Verstockt, B.(3);Vermeire, S.(4);Masamunt, M.C.(1);Giner, Á.(1);Ordás, I.(1);Fernández-Clotet, A.(1);Ricart, E.(1);Panés, J.(1);Salas, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP05: Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Sandborn, W.(1);Ding, Z.(2);Osterhout, R.(2);Feagan, B.(3);Danese, S.(4);Jucov, A.(5,6);Bhandari, B.R.(7);Raghupathi, K.(8);Olson, A.(9);Van Biene, C.(8);Ford, J.(10);Aranda, R.(9);Levesque, B.G.(9);Bruey, J.M.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Buisson1, E. Vazeille1, X. Hébuterne2, M. Fumery3, B. Pariente4, S. Nancey5, P. Seksik6, L. Peyrin-Biroulet7, M. Allez8, N. Ballet9, E. Billard10, S. Rodriguez10, B. Pereira11, N. Barnich10, CEALIVE Study Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared with ADA exposure
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Kanis*1, A. de Lima1, C. van der Ent2, C. van der Woude1

Created: Friday, 22 February 2019, 9:49 AM
DOP060: Human amnion epithelial cells and their conditioned media reduces intestinal inflammation and fibrosis in a murine model of chronic colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Kuk1,2*, J. Correia1,2, M. Alhomrani1,2,3, R. Lim3, W. Sievert1,2, A. Hodge1,2, G. Moore1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn's disease and ulcerative colitis in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siegel C.*1, Yang F.2, Eslava S.2, Cai J.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn’s Disease and Ulcerative Colitis in the United States
Year: 2017
Source: ECCO'17 Barcelona
Authors: Siegel C.
Anti-TNF agents, Corticosteriods, Patient choice, Thiopurines (AZA / MP)
Files: 1
DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of Acute Colitis
Year: 2018
Source: ECCO'18 Vienna
Authors: Kuk Nathan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of acute colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Kuk1,2*, J. Correia1,2, M. Alhomrani1,2,3, R. Lim3, W. Sievert1,2, A. Hodge1,2, G. Moore1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP061: Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Kanis*, A. de Lima, C. van der Woude

Created: Friday, 22 February 2019, 9:49 AM
DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim Y.H.*1, Ye B.D.2, Pesegova M.3, Alexeeva O.4, Osipenko M.5, Lahat A.6, Dorofeyev A.7, Salamon A.8, Fishman S.9, Levchenko O.10, Cheon J.H.11, Scribano M.L.12, Mateescu R.-B.13, Lee K.M.14, Eun C.S.15, Lee S.J.16, Lee S.Y.16

Created: Wednesday, 20 February 2019, 10:36 AM